Lighthorse Therapeutics is excited to announce the successful closing of a $62 million funding round, bolstering our mission to revolutionize cancer treatment through advanced cell therapy. Founded in 2018 by visionary leaders Alexander Kamb, Michael Gallo, and Paul Kang, our company stands at the forefront of innovative cancer therapies, specifically targeting solid tumors—areas of treatment that have long posed challenges in oncology. This latest funding round brings our total capital raised to an impressive $136 million, showcasing the confidence of our esteemed investors, including The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments, and Hartford HealthCare Endowment.
The funds will be strategically allocated to further our pioneering efforts in engineering T cells capable of identifying and targeting lost genetic material within tumors. This groundbreaking approach empowers us to selectively destroy cancer cells while preserving the surrounding healthy tissue, a critical advancement that could significantly improve patient outcomes in their battle against cancer. As we embark on this new phase of growth, we are more committed than ever to transforming the landscape of cancer therapy, turning the tide in the fight against this pervasive disease. At Lighthorse Therapeutics, we believe in a future where patients suffering from solid tumors have access to effective and targeted treatment options, and with this funding, we are one step closer to making that vision a reality. Stay tuned as we continue to push the boundaries of science and bring hope to those who need it most.
.png&w=3840&q=75)
